drugset
drugset / Trial / NCT05269667

A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention

NCT05269667 ↗

Phase 4 Terminated 4 enrolled Hoffmann-La Roche Chugai Pharmaceutical · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Objective of the trial is to describe the efficacy and safety of satralizumab in patients with aquaporin-4 (AQP4) antibody seropositive NMOSD, either treatment naive or inadequate responders to previous treatment with rituximab (RTX) (or its biosimilar)

Timeline

Start
2022-08-02
Primary completion
2023-10-26
Completion
2023-10-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Satralizumab Monoclonal antibody 120 mg Subcutaneous

Indications

neuromyelitis optica spectrum disorder with anti-AQP4 antibodies